Linda Schäker‐Hübner

Author

University of Bonn ORCID

Also Known As

L Schäker-Hübner, Linda Schäker-Hübner, Linda Schäker‐Hübner

Publications

393

Citations

H-Index

Concepts

All Affiliations

University of Bonn Leipzig University Heinrich Heine University Düsseldorf University of Pennsylvania University Hospital Leipzig

About

Linda Schäker‐Hübner is an author at University of Bonn specializing in biochemistry, medicine, and medicinal chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	83
2	Biochemistry	3	3	83
3	Natural Sciences	2	2	50
4	Chemical Biology	1	1	38
5	Chemistry	1	1	38

Linda Schäker‐Hübner

Publications

350

Citations

H-Index

Page 1

	Year	Citations
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties Viktoria Krieger, Alexandra Hamacher, Fangyuan Cao, Journal of Medicinal Chemistry	2019	46
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads Linda Schäker‐Hübner, Robin Warstat, Heinz Ahlert, Journal of Medicinal Chemistry	2021	45
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase <b>6</b> Beate König, P. R. Watson, Nina Reßing, Journal of Medicinal Chemistry	2023	41
Development of the first non-hydroxamate selective HDAC6 degraders Tim Keuler, Beate König, Nico Bückreiß, Chemical Communications ChromatinMedicinal ChemistryBiochemistryNatural SciencesHdac6-driven Diseases	2022	38
Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors Linda Schäker‐Hübner, Reza Haschemi, Thomas Büch, ChemMedChem	2022	35
HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer Robert Jenke, Denys Oliinyk, Tamara Zenz, Biochemical Pharmacology Tumor BiologyHdac InhibitorsHdac InhibitionBiochemistryGastrointestinal Oncology	2024	33
Development of Fluorinated Peptoid-Based Histone Deacetylase (HDAC) Inhibitors for Therapy-Resistant Acute Leukemia Nina Reßing, Julian Schliehe‐Diecks, P. R. Watson, Journal of Medicinal Chemistry	2022	29
Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy Fabian B. Kraft, Maria Hanl, Felix Feller, Pharmaceuticals	2023	25
Contilisant+Tubastatin A Hybrids: Polyfunctionalized Indole Derivatives as New HDAC Inhibitor-Based Multitarget Small Molecules with <i>In Vitro</i> and <i>In Vivo</i> Activity in Neurodegenerative Diseases Mireia Toledano‐Pinedo, Alicia Porro-Pérez, Linda Schäker‐Hübner, Journal of Medicinal Chemistry	2024	18
Hydrazide-Based Class I Selective HDAC Inhibitors Completely Reverse Chemoresistance Synergistically in Platinum-Resistant Solid Cancer Cells Fabian B. Kraft, Lukas Biermann, Linda Schäker‐Hübner, Journal of Medicinal Chemistry	2024	17

Page 1